Literature DB >> 6439233

Prophylaxis against ventricular arrhythmias in suspected acute myocardial infarction: a comparison of tocainide and disopyramide.

R A Allen-Narker, C J Roberts, A J Marshall, S C Jordan, D W Barritt, R M Goodfellow.   

Abstract

Five hundred and seventy one patients admitted to a coronary care unit with suspected acute myocardial infarction were considered for entry into a double-blind study. Two hundred and eighty-three patients were excluded, mainly because of recent treatment with beta-adrenoceptor blocking agents, life threatening arrhythmias requiring specific treatment and left ventricular failure presenting with hypotension or pulmonary oedema. Two hundred and eighty-eight entered the trial of whom 202 were subsequently confirmed to have had myocardial infarction. The effects of tocainide and disopyramide on ventricular arrhythmias were compared with placebo over the first 48 h period. The three treatments were given by a combination of intravenous infusion and oral administration. The doses used were tocainide 500 mg intravenously over 30 min plus 2800 mg orally over 48 h and disopyramide 150 mg intravenously over 30 min plus 1050 mg orally over 48 h. As judged by counts of ventricular premature beats, tocainide and disopyramide exerted a similar and significant antiarrhythmic effect. The median number of ventricular premature beats over the first 24 h of treatment was 58 on placebo compared with 30 on tocainide (P less than 0.05) and 19 on disopyramide (P less than 0.05). The corresponding figures for the second 24 h were 9, 6 and 2, respectively. There were eight deaths and three episodes of ventricular fibrillation with no significant differences between the three treatment groups. Sustained ventricular tachycardia was observed in one patient in the tocainide group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439233      PMCID: PMC1463540          DOI: 10.1111/j.1365-2125.1984.tb02535.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

Authors:  K I Lie; H J Wellens; F J van Capelle; D Durrer
Journal:  N Engl J Med       Date:  1974-12-19       Impact factor: 91.245

2.  Primary ventricular fibrillation complicating acute myocardial infarction.

Authors:  R W Dhurandhar; R L MacMillan; K W Brown
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

3.  Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man.

Authors:  D G McDevitt; A S Nies; G R Wilkinson; R F Smith; R L Woosley; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

4.  Kinetics of the oral antiarrhythmic lidocaine congener, tocainide.

Authors:  D Lalka; M B Meyer; B R Duce; A T Elvin
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

5.  Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction.

Authors:  K I Lie; H J Wellens; E Downar; D Durrer
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

6.  Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction.

Authors:  G Jennings; M S Jones; E M Besterman; D G Model; P P Turner; P H Kidner
Journal:  Lancet       Date:  1976-01-10       Impact factor: 79.321

7.  Electrocardiographic antecedents of primary ventricular fibrillation. Value of the R-on-T phenomenon in myocardial infarction.

Authors:  N El-Sherif; R J Myerburg; B J Scherlag; B Befeler; J M Aranda; A Castellanos; R Lazzara
Journal:  Br Heart J       Date:  1976-04

8.  Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide.

Authors:  R A Winkle; P J Meffin; J W Fitzgerald; D C Harrison
Journal:  Circulation       Date:  1976-12       Impact factor: 29.690

9.  Comparative study of tocainide and lidocaine in patients admitted for suspected acute myocardial infarction.

Authors:  N Rehnqvist; L Erhardt; C G Ericsson; G Olsson; G Svensson; A Sjögren
Journal:  Acta Med Scand       Date:  1983

10.  Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.

Authors:  N Zainal; D J Carmichael; J W Griffiths; E M Besterman; P H Kidner; A D Gillham; G D Summers
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

View more
  1 in total

Review 1.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.